title: Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research.
abstract: Trends in utilization and outcomes after autologous or allogeneic hematopoietic cell transplantation (HCT) for Burkitt lymphoma were analyzed in 241 recipients reported to the Center for International Blood and Marrow Transplant Research between 1985 and 2007. The autologous HCT cohort had a higher proportion of chemotherapy-sensitive disease, peripheral blood grafts, and HCT in first complete remission (CR1). The use of autologous HCT has declined over time, with only 19% done after 2001. Overall survival at 5 years for the autologous cohort was 83% for those in CR1 and 31% for those not in CR1. Corresponding progression-free survival (PFS) was 78% and 27%, respectively. After allogeneic HCT, overall survival at 5 years was 53% and 20% for the CR1 and non-CR1 cohorts, whereas PFS was 50% and 19%, respectively. The most common cause of death was progressive lymphoma. Allogeneic HCT performed in a higher-risk subset (per National Comprehensive Cancer Network guidelines) resulted in a 5-year PFS of 27%. Autologous HCT resulted in a 5-year PFS of 44% in those undergoing transplantation in the second CR.
authors.affiliation: Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA.
authors.forename: Leena V
authors.initials: LV
authors.lastname: Maramattom
authors.forename: Parameswaran N
authors.initials: PN
authors.lastname: Hari
authors.forename: Linda J
authors.initials: LJ
authors.lastname: Burns
authors.forename: Jeanette
authors.initials: J
authors.lastname: Carreras
authors.forename: William
authors.initials: W
authors.lastname: Arcese
authors.forename: Mitchell S
authors.initials: MS
authors.lastname: Cairo
authors.forename: Luciano J
authors.initials: LJ
authors.lastname: Costa
authors.forename: Timothy S
authors.initials: TS
authors.lastname: Fenske
authors.forename: Michael
authors.initials: M
authors.lastname: Lill
authors.forename: Cesar O
authors.initials: CO
authors.lastname: Freytes
authors.forename: Robert Peter
authors.initials: RP
authors.lastname: Gale
authors.forename: Thomas G
authors.initials: TG
authors.lastname: Gross
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Hale
authors.forename: Mehdi
authors.initials: M
authors.lastname: Hamadani
authors.forename: Leona A
authors.initials: LA
authors.lastname: Holmberg
authors.forename: Jack W
authors.initials: JW
authors.lastname: Hsu
authors.forename: David J
authors.initials: DJ
authors.lastname: Inwards
authors.forename: Hillard M
authors.initials: HM
authors.lastname: Lazarus
authors.forename: David I
authors.initials: DI
authors.lastname: Marks
authors.forename: David G
authors.initials: DG
authors.lastname: Maloney
authors.forename: Richard T
authors.initials: RT
authors.lastname: Maziarz
authors.forename: Silvia
authors.initials: S
authors.lastname: Montoto
authors.forename: David A
authors.initials: DA
authors.lastname: Rizzieri
authors.forename: Baldeep
authors.initials: B
authors.lastname: Wirk
authors.forename: James L
authors.initials: JL
authors.lastname: Gajewski
mesh_terms: D000293:Adolescent; D000328:Adult; D002051:Burkitt Lymphoma / Q000601:surgery*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014182:Transplantation, Autologous / Q000706:statistics & numerical data; D014184:Transplantation, Homologous / Q000706:statistics & numerical data; D016896:Treatment Outcome; D055815:Young Adult